Response Assessment and Prediction of Progression-Free Survival by 68Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy
At present, little is known about the molecular imaging-based response assessment of
prostate-specific membrane antigen (PSMA)-targeted radioligand therapy with 177Lutetium (177LuPSMA-617 RLT) in metastatic castration-resistant prostate cancer (mCRPC). Our study evaluated
the response to RLT using both molecular imaging and biochemical response assessments, and their
potential prediction of progression-free survival (PFS). Fifty-one consecutive patients given two cycles
of RLT at 6-week intervals were analyzed retrospectively. 68Ga-PSMA-11 PET/CT was obtained
about 2 weeks prior to the first and 4–6 weeks after the second cycle. Molecular imaging-based
response using SUVpeak and tumor-to-liver ratio (TLR) was determined by modified PERCIST criteria.
∆TLR and ∆SUV were significantly correlated with ∆PSA (p < 0.001, each). After a median follow-up
of 49 months, the median PFS (95% CI) was 8.0 (5.9–10.1) months. In univariate analysis, responders
showing partial remission (PRPSA and PRTLR) had significantly (p < 0.001, each) longer PFS (median:
10.5 and 9.3 months) than non-responders showing either stable or progressive disease (median: 4.0
and 3.5 months). Response assessment using SUVpeak failed to predict survival. In multivariable
analysis, response assessment using TLR was independently associated with PFS (p < 0.001), as was
good performance status (p = 0.002). Molecular imaging-based response assessment with 68Ga-PSMA11 PET/CT using normalization of the total lesion PSMA over healthy liver tissue uptake (TLR) could
be an appropriate biomarker to monitor RLT in mCRPC patients and to predict progression-free
survival (PFS) of this treatment modalit
